ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
May 12, 2022 08:30 ET
|
ABVC BioPharma, Inc.
Fremont, CA, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase...
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
May 10, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
May 05, 2022 08:30 ET
|
ABVC BioPharma, Inc.
New Process Improves Quality and Lowers Cost Fremont, CA, May 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company...
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
May 03, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
April 28, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
April 26, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
March 31, 2022 16:18 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver...
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
March 23, 2022 09:25 ET
|
ABVC BioPharma, Inc.
Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
February 02, 2022 08:00 ET
|
ABVC BioPharma, Inc.
Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites
January 05, 2022 08:30 ET
|
ABVC BioPharma, Inc.
Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage...